The analysis of day-to-day glucose excursions when switching from biphasic insulin 30 to insulin degludec and aspart

Trial Profile

The analysis of day-to-day glucose excursions when switching from biphasic insulin 30 to insulin degludec and aspart

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2017 Status changed from recruiting to completed.
    • 31 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top